Core Viewpoint - 23andMe Holding Co. intends to file a Form 25 Notification of Delisting with the SEC, which will remove its securities from Nasdaq listing and registration [1][2] Group 1: Company Actions - The company announced its intention to file a Form 25 on or about June 6, 2025, to facilitate its deregistration with the SEC [1] - 23andMe previously initiated voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the Eastern District of Missouri on March 23, 2025 [2] Group 2: Stock and Trading Information - Nasdaq suspended trading of 23andMe's Class A common stock on March 31, 2025, and notified the company about the filing of Form 25 [1] - Once the delisting becomes effective, the company plans to file a Form 15 to deregister with the SEC [2]

Core Viewpoint - Regeneron Pharmaceuticals has successfully bid for the assets of 23andMe Holding Co. for $256 million, aiming to enhance its leadership in genetics-guided research and drug development, pending bankruptcy court and regulatory approvals [1][2][3] Group 1: Acquisition Details - The planned acquisition includes 23andMe's Personal Genome Service, Total Health and Research Services, and Biobank assets, with the transaction expected to close in Q3 2025 [1] - Regeneron will operate 23andMe as a wholly owned subsidiary, continuing its consumer genomics services while excluding the Lemonaid Health business from the purchase [3][4] Group 2: Commitment to Data Privacy - Regeneron emphasizes its commitment to the privacy and ethical use of 23andMe's customer data, planning to work with an independent Customer Privacy Ombudsman to ensure compliance with privacy policies and laws [2][3] - The company has a proven track record in large-scale data management, having linked deidentified DNA sequences from nearly three million participants to electronic health records [2][3] Group 3: Strategic Vision - Regeneron aims to leverage its expertise in genetic research to support 23andMe's mission of helping individuals understand their DNA and improve personal health [2][3] - The acquisition aligns with Regeneron's broader strategy to utilize genetics research for advancing medical treatments and improving societal health outcomes [2][3][4]